Co-Diagnostics Enters Into Lease for New Laboratory Facility

- December 19th, 2017

Co-Diagnostics announced the leasing of a new CGMP-ready and Biological Safety Level 2 laboratory facility in Salt Lake City.

Co-Diagnostics (NASDAQ:CODX) announced the leasing of a new CGMP-ready and Biological Safety Level 2 laboratory facility in Salt Lake City, Utah.
As quoted in the press release:

Co-Diagnostics CEO Dwight Egan remarked, “The upgraded facility is nearly perfectly appointed with the necessary amenities to immediately commence production operations. This site will help us to reduce our dependence on outside locations to complete robust validations of the Company’s products, and represents the next step in our growth as a world-class developer of molecular diagnostics. Our trained personnel will now have the capacity to manufacture high-quality products that meet the standards of the U.S. Food and Drug Administration, preparing the Company to seek future FDA approvals for sale domestically and export abroad.”
Mr. Egan continued, “This is another important milestone in the development of Co-Diagnostics as an emerging leader in the molecular diagnostics industry. We are bringing disruptive technology to the market that will dramatically improve test accuracy by reducing false positives via our CoPrimers™ technology, and facilitate multiplexing to test for a broad range of disease states in a patient in a single test which will cut costs to healthcare systems. We are excited with the opportunities ahead in the coming years.”

Click here to read the full press release.


Leave a Reply